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Natural killer (NK) cells are classified as a member of the innate lymphoid cells (ILCs) 
group 1. ILCs have been recently identified and grouped on the basis of their phenotypi-
cal and functional characteristics. They are effectors of innate immunity and are involved 
in secondary lymphoid organ generation and tissue remodeling. NK cells are powerful 
cytotoxic lymphocytes able to recognize and eliminate tumor- and virus-infected cells 
by limiting their spread and tissue damage. The recognition of tumor cells is mediated 
by both activating and inhibitory receptors. While in hematological malignancies the role 
played by NK cells is widely known, their role in recognizing solid tumors remains unclear. 
Recently, tumor cell populations have been divided into two compartments: cancer- 
initiating cells (CICs) or cancer stem cells (CSCs) and senescent tumor cells. Here, CSC 
will be used. CSCs are a small subset of malignant cells with stem-like properties that 
are involved in tumor maintenance and recurrence due to their ability to survive to tradi-
tional therapies; they are, moreover, poorly recognized by T lymphocytes. Recent data 
showed that NK cells recognize in vitro cancer-initiating cells derived from colon cancer, 
glioblastoma, and melanoma. However, more in  vivo studies are urgently required to 
fully understand whether these new antitumor NK cells with cytotoxic capability may be 
considered in the design of new immunotherapeutic interventions.
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nK CeLLS
The large granular innate lymphoid cells (ILCs) are named as natural killer (NK) cells for their 
protective and cytotoxic role in infectious and tumor diseases. They play an active role in transplant 
rejection and in pathological conditions. The main effectors mechanisms of NK cells are lympho-
cytotoxicity and proinflammatory cytokine production. Recently, they were classified in Group 1 of 
the ILCs (1).
In human, NK cells are phenotypically characterized by the surface expression of molecules like 
CD56 and CD16 (FcγRIII) and by the absence of CD3, while in mice, they are defined as cells 
expressing NK1.1, DX5 and not expressing CD3. NK cells rely on a set of germ-line encoded activat-
ing and inhibitory receptors. The activating receptors include CD16, NKG2D, DNAM-1, and NKp46, 
all common to both human and mouse, while the other NK receptors (NCRs: NKp44 and NKp30) 
are expressed solely by human NK cells. Apart from the CD16 receptor recognizing Fc domain 
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antibodies, the other receptors interact with ligands on infected 
and transformed cells. Molecules associated with a “stress signa-
ture,” such as, MICA, MICB, ULBPs, and Hsp90 in human and 
Rae-1, MULT-1, and H60 in mouse, have been identified as major 
activating ligands (2). Other activating NK ligands are PVR and 
NECTIN-2 bound by DNAM-1, expressed both in human and 
mice. NCR ligands are still unknown, except for NKp30, whose 
ligands are B7-H6, BAG-6, and Gal-3 (3, 4).
The inhibitory receptors of NK cells interact with major his-
tocompatibility complex (MHC-I) molecules. In human, most of 
these receptors belong to the family of killer cell immunoglobu-
lin like receptors (KIRs) that directly bind to certain HLA-A, 
-B, and  -C alleles. KIRs are highly polymorphic receptors that 
interact with MHC-I molecules and elicit inhibitory or activat-
ing signals. Their name is correlated with the number of Ig-like 
domains in their extracellular regions and with the presence of 
a long (inhibitory) or short (activating) cytoplasmic tail. Other 
types of inhibitory and activating NK cell receptors are the lectin-
like heterodimers of NKG2 family. The best-known members 
are the inhibitory heterodimer CD94/NKG2A and its activating 
counterpart CD94/NKG2C, both recognizing the non-classical 
MHC class I molecule, HLA-E. In mice, the inhibitory receptors 
belong to the superfamily of lectin-like type II integral membrane 
proteins, known as Ly49 and CD94/NKG2A receptors.
The lack or reduced expression of MHC-I on the target cells’ 
surface leads to “missing self ” recognition. There are clinical 
observations and ongoing clinical trials based on the idea that NK 
cells transferred from one individual to a non-MHC-I-matched 
patient can exert antileukemic effects based on “missing self ” 
recognition (5).
In both species, the fully matured highly cytotoxic NK phe-
notype is acquired after a, still poorly understood, MHC class I 
molecule-dependent ontogenic process. The NK cells ontogeny 
process has been termed “education – licensing – arming/disarm-
ing” (6, 7). Recently, Kärre and coworkers have proposed to explain 
the NK cells’ education in the “Rheostat Model” (8). The “Rheostat 
Model” postulates that education of NK cells represents a tuning 
mechanism that goes on continuously and reversibly accordingly 
to the MHC environment, even after NK cell maturation. This 
model has implications for immunotherapy based on exploiting 
“missing self ” reactivity when NK cells are transferred to a cancer 
patient from a healthy, non-MHC-matched individual. If the NK 
cells are “re-tuned” in the new environment, as proposed in the 
rheostat model, this may affect their efficacy to react against the 
recipient’s leukemia cells and can influence the reactivity of NK 
cells against tumor cells in different situations. It has been shown 
that NK cells can exert antitumor effects in the new host environ-
ment. Recently, Wagner and coworkers provided further support 
to the rheostat model demonstrating that NK cells infused in a 
recipient become tolerant to healthy cells representing “missing 
self ” in the new environment, while the re-tuned NK cells will 
retain activity against tumor cells representing “missing self,” due 
to a higher expression of ligands for activating NK receptors on 
tumor cells (9).
Another new concept that has contributed to change our 
knowledge about the NK cells biology derives from the obser-
vations made during human and mice CMV infection, where 
NK cell subsets recognizing CMV-infected cells expanded. The 
expanded CMV-specific population has been proposed to be a 
relevant NK cell memory subset able to provide immunity in the 
second infection round (10–12).
Therefore, the information that are now available on the NK 
cells biology are pushing the field toward their use in clinical 
settings.
nK AnD CAnCeR
The history of NK cells has evolved closely related with the his-
tory of cancer immunotherapy since they were discovered in 
the 1970s for their capability to target and kill cancer cells. NK 
cells preventing leukemia relapse in mismatched hematopoietic 
stem cell transplant (HSCT) patients stirred a renewed interest 
in the use of NK cells in the fight against cancer. They are the 
most efficient effectors against tumors and are considered suitable 
candidates for adoptive immunotherapy of both hematological 
and non-hematological malignancies (13–15).
Nearly 50 years after their discovery, we are now starting to 
realize the potential of these NK cells in tumor immune therapy 
trials.
CAnCeR STeM CeLLS
The processes underlying the etiology of cancer have been the 
source of several theories for a century (16, 17).
It was demonstrated that any cell exposed to genotoxic stress 
acquires multiple genetic mutations and may give rise to a tumor 
(18). More recently, Tomasetti and Vogelstein demonstrated that 
stochastic influences are the major contributors to cancer overall, 
often even more than hereditary or external environmental 
factors. Many genomic changes occur simply by chance during 
DNA replication rather than as a result of carcinogenic factors. 
Considering the number of mutations needed for a malignant 
transformation, it is conceivable that these can only accumulate 
in long-lived cells (stem cells) (19).
Therefore, cancer stem cell hypothesis postulates that only a 
small subset of cells, termed cancer-initiating cells (CICs) or can-
cer stem cells (CSCs), is able to give rise to and maintain tumors 
(20–22), even though for transplanted murine tumors, such as 
melanoma, the relevance of CSCs has been questioned (23).
Cancer stem cells constitute a self-renewing stem cell-like 
population, having an asymmetric proliferating pattern respon-
sible for the progression, metastasis, resistance to treatment, and 
recurrence of several tumors (24–26).
Compelling data support the cancer stem cell model in vari-
ous human cancers including malignant embryonic tissues cell 
cancers (27, 28), leukemias (29, 30), breast cancers (31), brain 
cancers (32), and colon cancers (33–35). Based on the different 
tumor types, the CSCs were identified by the expression of dif-
ferent markers, such as CD133+ CD166+, CD44+, CD29+, CD24+, 
EpCAM, Lgr5, aldehyde dehydrogenase, and a few others (36).
The main feature of the CSCs is that a small amount of 
them (up to 100 cells) may transfer disease upon transplan-
tation into immune-compromised NOD/SCID mice (34, 
35). Some markers have been identified that distinguish the 
3Tallerico et al. NK Cells Trageting of CSCs
Frontiers in Immunology | www.frontiersin.org May 2016 | Volume 7 | Article 179
leukemogenic/tumorigenic cancer cells (leukemogenic CSC) 
from the bulk populations of non-leukemogenic/tumorigenic 
cells ( non-leukemogenic CSC). The ability to predict which cells 
are tumorigenic based on marker expression indicates that the 
tumorigenic cells are intrinsically different from non-tumorigenic 
cancer cells.
nK AnD CSC
Cancer stem cells have been suggested to be responsible for 
the hematological metastatic spreading of solid tumors (37). 
The asymmetrical growth and their low rate of proliferation 
make them resistant to conventional radiotherapy and chemo-
therapy. Therefore, to prevent CSCs contribution in sustaining 
tumor progression, several groups have evaluated whether 
the effector immune cytotoxic cells (NK cells, CD8 T cells, 
and γδ T cells) could eliminate the tumor stem compartment. 
However, the low level of MHC class I expression reported 
for CSCs predicts a low efficiency of CSCs targeting by CD8+ 
cytotoxic T lymphocytes, while recent data demonstrate that 
once the CSC is sensitized with bisphosphonate zoledronate, 
the human γδ T cells could efficiently target CSCs in  vitro 
(38). The cytotoxic interaction was regulated via TCR and to 
a lesser extent by NKG2D receptors (38). On the other hand, 
data have shown that NK cells, mainly in vitro, selectively kill 
human colon-derived CSCs without any pharmacological 
pretreatment (39), melanoma (40), and glioblastoma (41). The 
molecular mechanisms leading the NK cell recognition of CSC 
have been partially elucidated.
In our laboratory, we demonstrate that freshly purified autolo-
gous and allogeneic NK cells show a robust cytotoxic effect on 
CIC derived from colorectal carcinoma cells (CRC), whereas the 
CRCs were less susceptible to the NK lysis, Tallerico et al. (39). 
The capability to preferentially recognize and kill colorectal-CIC 
is correlated with a higher expression of NCR ligands (in particu-
lar, NKp30 and NKp44) and a lower expression of MHC class I on 
the surface of CSCs compared to their tumor counterparts (39).
In another pathological setting, Pietra and colleagues (40) 
analyzed different melanoma cells derived from metastatic pri-
mary cultures or from established cell lines. These cells have a 
highly heterogeneous expression of different stem cell-associated 
markers including CD133, c-kit/CD117, and p75 neurotrophin 
receptor/CD271. IL-2-activated NK cells are able to recognize 
and lyse melanoma cells enriched CSC through the involvement 
of a different combination of activating NK receptors. Indeed, 
NK cells efficiently kill melanoma cells resistant to radiotherapy, 
either with ability to form melanospheres in vitro or having the 
stem cell-associated marker CD133 expression, underlying the 
possibility to use a novel NK-based immunotherapeutic strategy 
to eliminate CSC (42).
This was demonstrated also by Castriconi and colleagues (41) 
in glioblastoma patients, in which CSCs were isolated and charac-
terized for typical markers of neural stem cells. They were capable 
of partial multilineage differentiation in vitro and gave origin to 
infiltrating tumors when orthotopically injected in NOD/SCID 
mice. These cells, characterized by stem cell-like properties, are 
well killed by allogeneic and autologous NK cells activated by IL-2 
or IL-15. The NK-mediated killing of glioblastoma cells (GBM) 
has been identified by the low levels of HLA class I both classical 
(HLA-A, -B, -C) and non-classical (HLA-E) molecules and by 
the expression of DNAM-1 and NKp46 activating NK recep-
tors. Moreover, most of GBM cells express different amounts of 
NKG2D ligands, while all GBM express PVR and NECTIN-2 
(DNAM-1 ligands) (41).
The Pietra and the Castriconi studies provide novel thera-
peutic approaches based on the use of activated NK cells useful 
to eradicate tumor cells residuals after surgery or a traditional 
therapy.
Thus, these combined studies confirm that the molecular 
mechanisms behind the NK cell-mediated recognition of CSC 
rely on their loss or low MHC class I expression and increased 
amounts of activating NK ligands, on their cell surfaces. It should 
be noted that the low expression of MHC class I is not always 
the main mechanism by which NK cells recognize tumor cells. 
Tumors could lose or not their MHC class I expression, however, 
they could acquire NK receptor activating ligands on the cell 
membrane leading to a specific NK cell recognition.
A crucial issue to exploit the NK cells to target CSC is to vali-
date these in vitro observations in experimental in vivo models.
So far, very few in  vivo studies address the potential of NK 
cells to ablate the CSC compartment from the tumor population.
Recently, Ames and colleagues (42) showed that NK cells kill 
CSCs from different kinds of tumors, through the interaction 
of the NKG2D activating receptor with its ligand (MICA/B). 
They have shown, ex vivo and in vivo, the efficacy of the NK cell 
therapy to target CSCs. They implanted human tumor cell lines 
in NOD SCID gamma (NSG) mice and then injected activated 
NK cells. After NK infusion, they sacrificed mice and observed 
the number of tumor colonies when homogenized lung cells were 
plated in a lung colony formation assay. The colonies that did 
develop in NK cell-treated mice showed an impressive reduction 
in size, consistent with NK cell targeting of stem-like tumor cells. 
In mice with established orthotopic pancreatic tumors that were 
treated with NK infusion, Ames observed by bioluminescence, 
the reduction of the tumor size, demonstrating the therapeutic 
efficacy of NK cells (42). All the discussed data are summarized 
in Table 1.
COnCLUSiOn
Different promising strategies to directly attack CSCs have 
been proposed using antibody-based therapies (43) by blocking 
pathways important for homing and engraftment (CD44), self-
renewal (CD27), protection against phagocytosis (CD47), or by 
strongly activating CD8+ T cells (CTLs) specific for CSC antigens 
or simply by forcing CSC into cell cycle. However, their thera-
peutic success has been limited. This calls for new approaches to 
target the CSCs compartment as a valid anticancer therapy.
The recent findings discussed here showed that the immune 
system, in particular the innate part (dendritic, NK, and γδ 
T  cells), can efficiently cooperate to eliminate CSC; this allow 
us to hypothesize that a promising avenue to eradicate CSC 
might lie in harnessing NK and γδ T cells. However, the in vivo 
functional outcome of NK–stem cell interplay may also result 
TABLe 1 | Phenotypes and nK cells recognition pattern of cancer stem cells and related tumors.
Human tumor Type PvR neCTin-2 MiCA MiCB ULBPs nCR ligands HLA nK cell recognition
Colorectal carcinoma (39) Tumor NC NC NC NC NC +/− + +/−
NKp30L HLA-A, -B, -C
NKp44L
Cancer stem cells NC NC NC NC NC + +/− ++
NKp30L HLA-A, -B, -C
NKp44L
Melanoma (40) Tumor +/− +/− +/− ND +/− ND + +
ULBP2 HLA-A, -B, -C
Cancer stem cells +/− +/− +/− ND +/− ND − +
ULBP3 HLA-A, -B, -C
Glioblastoma (41) Tumor − − − − − ND + +/−
HLA-E
Cancer stem cells + + +/− +/− +/− ND + ++
HLA-A, -B, -C
HLA-E
Pancreatic adenocarcinoma (42) Tumor ND ND − − ND − NC +/−
Cancer stem cells ND ND + + ND − NC ++
Sarcoma Ewing (42) Tumor ND ND − − ND − NC +/−
Cancer stem cells ND ND + + ND − NC ++
Liposarcoma (42) Tumor ND ND ND ND ND ND ND +/−
Cancer stem cells ND ND ND ND ND ND ND ++
Breast carcinoma (42) Tumor ND ND ND ND ND ND ND +/−
Cancer stem cells ND ND ND ND ND ND ND ++
Glioblastoma (42) Tumor ND ND ND ND ND ND ND +/−
Cancer stem cells ND ND ND ND ND ND ND ++
NC, no change between tumor and CSC; ND, not detected.
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in NK anergy (44, 45). Such NK cell dysfunctional plasticity is 
believed to have a major impact in NK cell-based immunothera-
peutic approaches and deserves a deeper understanding through 
in vivo models.
Several studies (46) have demonstrated that chemotherapy 
either induce or increase the CSCs susceptibility to NK- and γδ T 
cell-mediated killing. Therefore, combination of immune-based 
therapies with chemotherapy could be beneficial in the treatment 
of many cancers.
The current failure of standard therapies is attributed to a 
small fraction of the primary cell population with stem-like 
characteristics (CSC), such as self-renewal and differentiation. 
So, it is imperative to target all CSCs within the tumor to pre-
vent relapse. Even though different aspects of CSCs have been 
explored in recent targeting strategies, their success has been very 
limited probably because an exhaustive comprehension of their 
basic biology and evolution is far from being clarified.
In order to eradicate the CSCs, we need to act at multiple 
levels: increasing their sensitivity to chemotherapy and to novel 
compounds, stimulating or reactivating a tumor-specific immune 
response selectively directed against the CSCs, enhancing the 
efficacy of therapies currently in use with a selective induction 
of the immune response, and testing the antitumor and immune-
stimulating properties of new compounds. Further investigations 
are necessary to better understand the basic biology of immune 
recognition of CSC, which may be rapidly translated into innova-
tive therapeutic approaches for the treatment of different forms 
of cancer.
Moreover, in accordance with our and Pietra, Castriconi, 
and Ames studies, NK-mediated killing is a possible candidate 
for targeting CSCs following the depletion of non-CSCs by 
anti-proliferative therapies. These studies focused on possible 
strategies to eradicate CSCs from established tumors; taking 
together the data produced, it is conceivable to think that NK 
cells can selectively recognize CSC compartments of several 
solid tumors, in vitro. At this stage, however, only a few studies 
are available on the in vivo NK cell-mediated CSC eradication 
and tumor control.
Therefore, more in vivo studies are necessary to address the 
hypothesis that NK cells can eradicate the CSCs population in 
a pathophysiological setting and to establish new immune- 
intervention strategies in solid tumors that can be readily 
 transferred in new clinical trials.
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